Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Source: 
Motley Fool
snippet: 

Pfizer (NYSE: PFE) is out to an early lead with Vyndaqel, a drug that treats cardiomyopathy caused by transthyretin (TTR)-mediated amyloidosis (ATTR-CM), in which the TTR protein aggregates in the heart and ultimately interferes with its function. During the third quarter, the drug's first full quarter on the market in the U.S., Pfizer logged $79 million in sales of Vyndaqel.